DNLI News and Press, Denali Therapeutics Inc. From 05/03/21

Denali Therapeutics (DNLI) announces final results from Phase 1 and 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen (BIIB) as a potential treatment of Parkinson’s disease.Safety and biomarker goals were met in both...

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease BIIB122/DNL151 demonstrated a safety profile supporting continued development in patients with Parkin...

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire CAMBRIDGE, Mass. , March 30, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the pot...

Denali released some early positive data. Meanwhile its market cap has reduced by 25%. While $7.5bn is still a lot for an early stage biotech, it is less than what it was a few months ago. For further details see: Denali Is Getting To Be More And More Interesting

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At HC Wainwright Global Life Sciences Conference

Shares of Denali Therapeutics (NASDAQ: DNLI) popped on Thursday, with the stock rising 12.3% as of 3:28 p.m. EST. The nice gain came after the biotech announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to DNL310 in treating Hunter syndrome, whi...

The FDA has granted the Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (mucopolysaccharidosis type II).DNL310, an investigational brain-penetrant enzyme replacement therapy developed by Denali Therapeutics ([[DNLI]] +11.1%) is currently...

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that...

Centogene N.V. (CNTG) announced today that the company has reached a significant milestone in its Rostock International Parkinson's Disease ("ROPAD") study with the recruitment and genetic testing of 10,000 participants.Involving over 120 study sites across the globe, the global obs...

Denali Therapeutics (DNLI): Q4 GAAP EPS of $1.91 beats by $2.44.Revenue of $316.81M ($4.6M Y/Y) beats by $238.6M.Press Release For further details see: Denali Therapeutics EPS beats by $2.44, beats on revenue